Fundraising FoxDiadem
2 known investors
Find your way into Diadem
Sign up to see every warm intro you have to Diadem
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Diadem team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Diadem is a diagnostics company developing AlzoSure, a plasma/blood-based test that uses a proprietary antibody targeting a specific conformation of the p53 protein to predict and diagnose Alzheimer's disease. The test aims to provide early, non-invasive diagnosis and to support patient recruitment for Alzheimer's drug development clinical trials.
Investors · 2
How we know: CDP Venture Capital's portfolio page · the VCSheet dataset · Not right? Tell us
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2.5M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Diadem do?
- Diadem is a diagnostics company developing AlzoSure, a plasma/blood-based test that uses a proprietary antibody targeting a specific conformation of the p53 protein to predict and diagnose Alzheimer's disease. The test aims to provide early, non-invasive diagnosis and to support patient recruitment for Alzheimer's drug development clinical trials.
- Who are Diadem's investors?
- Diadem's investors include CDP Venture Capital, Seed Healthcare.